C3.ai Digital Transformation Institute Announces Call for Proposals for AI to Transform Cybersecurity and Secure Critical Infrastructure
21.12.2021 17:00:00 EET | Business Wire | Press release
The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to advance the science of digital transformation with artificial intelligence (AI) designed to harden information security (Infosec) and secure critical infrastructure.
“Cybersecurity is an existential issue,” said Thomas M. Siebel, Chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are assembling the best minds on the planet to develop innovative AI to attain a step-function improvement in securing IT, OT, and critical infrastructure systems.”
“Advanced AI and machine learning offer the best opportunity to design robust defensive systems,” said C3.ai DTI Co-Director S. Shankar Sastry of UC Berkeley, whose area of research expertise is cybersecurity. “This call for proposals will help design the defenses necessary to securely shield the digital transformation of our economy.”
“We aim to develop AI techniques to identify and neutralize malware, ransomware, phishing attacks, and prevent the weaponization of innocent insiders,” said C3.ai DTI Co-Director R. Srikant of the University of Illinois at Urbana-Champaign, an expert in AI and networks.
Immediate Call for Proposals: AI to Transform Cybersecurity and Secure Critical Infrastructure.
Topics for research awards may include, but are not limited to, the following:
- AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
- AI-enabled network and system crawlers that can continuously search and identify persistent access mechanisms (backdoors), bots, remote access toolkits (RATS), stagers, and Trojans
- AI forensics and attribution techniques to identify sources of attacks
- AI techniques to automate simulated adversarial attacks to identify system and network vulnerabilities
- AI techniques to accurately identify and enable the neutralization of phishing attacks
- Change management techniques to prevent the weaponization of innocent insiders
- AI techniques to detect the presence of advanced persistent threats and insider threats
- AI-enabled network and/or system crawlers that access and continuously evaluate system security levels
- AI techniques, perhaps in supervised or unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
- Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
- AI techniques to identify concentration risk in the software and computer supply chain
- Change management to transform organizational behavior to manifest best practices in cyber hygiene
- Techniques to respond to attacks at the organizational and societal level
This third call for proposals is open now, with a submission deadline of February 7, 2022. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Award winners will be announced in March 2022, with a start date around June 1, 2022. Award winners may take part in the annual C3.ai DTI Research Symposium, to be held March 22-24, 2022, in Miami, Florida.
Up to USD $10 million in cash awards will be funded from this third call, ranging from USD $100,000 to $1,000,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite hosted on the Microsoft Azure Cloud, and access to high-performance computing resources at the Lawrence Berkeley National Laboratory and the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign. All science developed from C3.ai DTI funded projects accrues to the public domain.
Establishing the New Science of Digital Transformation
C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.
About C3.ai Digital Transformation Institute
C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005200/en/
Contact information
C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
Tel. +1 510-295-9685
Kstann@berkeley.edu
Press Contact
Lisa Kennedy
(415) 914-8336
pr@c3.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
